Tyra Biosciences Inc 's Cash & cash equivalent grew by 97.86 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Tyra Biosciences Inc 's Quick Ratio to 212.22, above Tyra Biosciences Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 90 other companies have achieved higher Quick Ratio than Tyra Biosciences Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 179 to 338.

Explain Quick Ratio?
How much Cash & cash equivalents TYRA�s has?
What are TYRA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/TYRA/financial-strength

https://api.csimarket.com/api/v1/companies/TYRA/fundamentals

https://api.csimarket.com/api/v1/companies/TYRA/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

TYRA Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-79.21 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	154.82 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	212.22	Subscribe	Subscribe	Subscribe	Subscribe
TYRA's Total Ranking	# 338	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-89.04 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	97.86 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 91
Healthcare Sector	# 132
Overall Market	# 338

Quick Ratio Statistics
High	Average	Low
83.57	35.22	5.75
(Dec 31 2021)		(Dec 31 2020)

Financial Statements
Tyra Biosciences Inc 's Current Liabilities	$ 3 Millions	Visit TYRA's Balance sheet
Tyra Biosciences Inc 's Cash & cash equivalent	$ 701 Millions	Visit TYRA's Balance sheet
Source of TYRA's Sales		Visit TYRA's Sales by Geography

Cumulative Tyra Biosciences Inc 's Quick Ratio

TYRA's Quick Ratio for the trailling 12 Months

TYRA Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	20.97 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	37.55 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	23.94	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 2971	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-15.09 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	33.55 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to TYRA Financial Strength Comparisons >> Go to Compare TYRA Quick Ratio to its Competitors

On the trailing twelve months basis TYRA Cash & cash equivalent more than doubled by 154.82 % in Q3 2026 year on year, while Current Liabilities dropped to $3 millions, this led to increase in in Tyra Biosciences Inc 's Quick Ratio to 23.94, Quick Ratio remained below TYRA average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 406 other companies have achieved higher Quick Ratio than Tyra Biosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2960 to 2971.

Explain Quick Ratio?
How much Cash & cash equivalents TYRA�s has?
What are TYRA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 407
Healthcare Sector	# 805
Within the Market	# 2971

trailing twelve months Quick Ratio Statistics
High	Average	Low
63.11	35.45	18.07
(Jun 30 2022)		(Mar 31 2026)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Tyra Biosciences Inc	212.22	$ 700.548 Millions	$ 3.301 Millions
Indaptus Therapeutics Inc	184.44	$ 34.604 Millions	$ 0.188 Millions
Vogenx, Inc.	97.47	$ 82.118 Millions	$ 0.842 Millions
Processa Pharmaceuticals Inc	96.73	$ 180.205 Millions	$ 1.863 Millions
Veradermics Inc	89.45	$ 927.861 Millions	$ 10.373 Millions
Arca Biopharma Inc	83.92	$ 1,206.587 Millions	$ 14.377 Millions
Incannex Healthcare Inc	65.89	$ 68.267 Millions	$ 1.036 Millions
Q32 Bio Inc	56.05	$ 289.587 Millions	$ 5.167 Millions
Rallybio Corporation	51.94	$ 90.693 Millions	$ 1.746 Millions
Enliven Therapeutics Inc	45.41	$ 884.351 Millions	$ 19.473 Millions

Date modified: 2026-11-11T14:04:20+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.